Steven Rosenberg
Potomac, MDNPI 1376879312
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Gilead.
Across 1 payment — averaging $26.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$26
Across 37 payments — averaging $636,928 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$19.9M
- Clinigen, Inc.$2M
- Iovance Biotherapeutics, Inc.$1.6M
What the payments were for
- Food & beverage$26100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $26 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.